

Special Issue

State of the Art and Advances in Kaposi Sarcoma

Message from the Guest Editor

Kaposi Sarcoma (KS) is a rare malignancy originating from endothelial cells. The disease is caused by human herpesvirus-8 (HHV-8), also known as Kaposi Sarcoma-associated herpesvirus (KSHV).

The diagnosis of KS relies primarily on histological examination, and techniques such as immunohistochemistry for HHV-8 latent nuclear antigen (LNA-1) and in situ hybridization are refining diagnostic accuracy.

In terms of therapy, there are different traditional approaches like chemotherapy, radiotherapy, and reduction in immunosuppressive treatment. The integration of optimized antiretroviral therapy (ART) remains pivotal in controlling HIV-associated KS and preventing disease progression. On the other hand, immunotherapy has shown promising early results in clinical trials. Targeted therapies are also emerging as potential options.

This Special Issue will focus on the state of the art and the latest research results in the fields of pathogenesis, diagnosis, and therapy of Kaposi Sarcoma. Original research or review articles are welcome to further enrich our collective understanding and advance patient care.

Guest Editor

Dr. Athanasia Tourlaki

1. Department of Physiopathology and Transplantation, University of Milan, Milan, Italy
2. Dermatology Unit—Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Pace, 9, Milan, Italy

Deadline for manuscript submissions

23 September 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/223425

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)